On January 14, BMO Capital reaffirmed an 'Outperform' rating for Eli Lilly and Company (NYSE:LLY), setting a price target of $1,200. This matches the consensus one-year median target price and suggests an upside potential of 16.36%. The firm expressed confidence in the company's solid leadership position in the obesity treatment space and beyond for 2026 and the years ahead.
BMO Capital noted that growth and certainty for Eli Lilly's incretin business are supported by broadening access, the expected launch of orforglipron, and the company's expanding portfolio. While maintaining its leadership in the obesity market, Eli Lilly also has a strong presence in other disease areas, particularly Lp(a), which contributes to its long-term growth outlook.
Two days earlier, Eli Lilly announced a partnership with NVIDIA to develop an AI co-innovation lab focused on pharmaceutical research. The leading entities plan to invest up to $1 billion in talent, infrastructure, and computing resources over a five-year period.
Eli Lilly and Company, based in Indiana, discovers, develops, and markets human pharmaceuticals. Founded in 1876, the company is committed to improving people's lives globally.